Ranbaxy Laboratories
- All
- News
- Videos
-
Ex-Ranbaxy Promoter Malvinder Singh Arrested By Enforcement Directorate
Pharmaceutical giant Ranbaxy Laboratories' ex-promoter Malvinder Singh has been arrested by the Enforcement Directorate in a money laundering case.
-
Ranbaxy Ex-Promoters Malvinder, Shivinder Singh Arrested In Fraud Case
Pharmaceutical giant Ranbaxy's ex-promoters Shivinder Singh and his older brother Malvinder Singh were arrested on Thursday in a Rs 740-crore fraud case.
-
Ex-Ranbaxy Promoter Fined Nearly 18 Crore Over Court Disobedience
The Delhi High Court Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million Singapore dollars, which he obtained by selling his shares in a company in violation of court's direction.
-
Fortis Healthcare Co-Owner Restrained From Selling Properties Over Loan Default
The Delhi Debts Recovery Tribunal (DRT) has restrained former CEO of Ranbaxy Laboratories and the co-owner of Fortis Healthcare, Malvinder Mohan Singh, from selling a posh property in Lutyen's Delhi and some other assets in a bank loan default case.
-
Sun Pharma Says US Regulator To Lift Ban On Mohali Drug Plant
Sun gained the plant along with its acquisition of Ranbaxy Laboratories in 2015 and has been attempting to fix quality control problems there that the US Food and Drug Administration (FDA) identified in 2013.
-
Sun Pharma Gets CCI Nod to Sell Two Ranbaxy Divisions to Strides
Drug major Sun Pharma has received approval from competition watchdog CCI to sell the erstwhile Ranbaxy Laboratories' two divisions in the central nervous system (CNS) segment in India to Strides Shasun for Rs 165 crore.
-
Strides Arcolab Surges 5% on Sun Pharmaceutical Industries Deal
Shares of Strides Arcolab surged nearly 4 per cent to Rs 1,191 at its day's high after the Bangalore-based pharma company reached a deal with Sun Pharmaceutical Industries Ltd to buy two marketing divisions of erstwhile Ranbaxy Laboratories.
-
Sun Pharma to Sell Two Marketing Divisions to Strides Arcolab
Sun Pharma, which last year bought domestic peer Ranbaxy Laboratories Ltd in July, said it may sell low-margin businesses it deemed do not hold long-term value.
-
Sun Pharma Looking to Divest Ireland Plant
Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories Ltd.
-
Sun Pharma Q1 Profit Falls 60% to Rs 479 Cr
Sun Pharma on Tuesday reported a 60 per cent dip in consolidated net profit at Rs 478.96 crore for the fiscal first quarter that ended on June 30, 2015, pulled down by impairment charges and an expense of Rs 685.17 crore on account of integration and optimisation post-Ranbaxy merger.
-
Sun Pharma's Open Offer for Zenotech Stake Gets Tepid Response
Sun Pharma decided to make the open offer after its acquisition of Ranbaxy, which had held significant stake in Zenotech.
-
Sun Pharma Slumps 16% on Sales Warning
Analysts estimate a roughly 8-10 per cent hit to profit for the year as Sun Pharma struggles to fix manufacturing problems at one of its own key plants and those of Ranbaxy Laboratories, the troubled rival it bought last year.
-
Sun Pharma Expects Ranbaxy Costs to Hit FY16 Revenue
Sun Pharmaceutical Industries Ltd, India's largest drug maker, said on Monday that its revenue in fiscal year 2016 would be flat at best as it struggles to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.
-
Sun Pharma Misses Profit Estimates in Q4 on Ranbaxy Costs
Sun Pharmaceutical Industries Ltd, India's largest drug maker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd.
-
Complaint Against Sun Pharma for Anti-Trust Violations in US
Drug major Sun Pharmaceutical Industries on Friday said it is reviewing a complaint filed against it and its subsidiaries by Meijer Inc alleging anti-trust and other violations in connection with Ranbaxy securing market exclusivity for certain products.
-
Ex-Ranbaxy Promoter Malvinder Singh Arrested By Enforcement Directorate
Pharmaceutical giant Ranbaxy Laboratories' ex-promoter Malvinder Singh has been arrested by the Enforcement Directorate in a money laundering case.
-
Ranbaxy Ex-Promoters Malvinder, Shivinder Singh Arrested In Fraud Case
Pharmaceutical giant Ranbaxy's ex-promoters Shivinder Singh and his older brother Malvinder Singh were arrested on Thursday in a Rs 740-crore fraud case.
-
Ex-Ranbaxy Promoter Fined Nearly 18 Crore Over Court Disobedience
The Delhi High Court Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million Singapore dollars, which he obtained by selling his shares in a company in violation of court's direction.
-
Fortis Healthcare Co-Owner Restrained From Selling Properties Over Loan Default
The Delhi Debts Recovery Tribunal (DRT) has restrained former CEO of Ranbaxy Laboratories and the co-owner of Fortis Healthcare, Malvinder Mohan Singh, from selling a posh property in Lutyen's Delhi and some other assets in a bank loan default case.
-
Sun Pharma Says US Regulator To Lift Ban On Mohali Drug Plant
Sun gained the plant along with its acquisition of Ranbaxy Laboratories in 2015 and has been attempting to fix quality control problems there that the US Food and Drug Administration (FDA) identified in 2013.
-
Sun Pharma Gets CCI Nod to Sell Two Ranbaxy Divisions to Strides
Drug major Sun Pharma has received approval from competition watchdog CCI to sell the erstwhile Ranbaxy Laboratories' two divisions in the central nervous system (CNS) segment in India to Strides Shasun for Rs 165 crore.
-
Strides Arcolab Surges 5% on Sun Pharmaceutical Industries Deal
Shares of Strides Arcolab surged nearly 4 per cent to Rs 1,191 at its day's high after the Bangalore-based pharma company reached a deal with Sun Pharmaceutical Industries Ltd to buy two marketing divisions of erstwhile Ranbaxy Laboratories.
-
Sun Pharma to Sell Two Marketing Divisions to Strides Arcolab
Sun Pharma, which last year bought domestic peer Ranbaxy Laboratories Ltd in July, said it may sell low-margin businesses it deemed do not hold long-term value.
-
Sun Pharma Looking to Divest Ireland Plant
Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories Ltd.
-
Sun Pharma Q1 Profit Falls 60% to Rs 479 Cr
Sun Pharma on Tuesday reported a 60 per cent dip in consolidated net profit at Rs 478.96 crore for the fiscal first quarter that ended on June 30, 2015, pulled down by impairment charges and an expense of Rs 685.17 crore on account of integration and optimisation post-Ranbaxy merger.
-
Sun Pharma's Open Offer for Zenotech Stake Gets Tepid Response
Sun Pharma decided to make the open offer after its acquisition of Ranbaxy, which had held significant stake in Zenotech.
-
Sun Pharma Slumps 16% on Sales Warning
Analysts estimate a roughly 8-10 per cent hit to profit for the year as Sun Pharma struggles to fix manufacturing problems at one of its own key plants and those of Ranbaxy Laboratories, the troubled rival it bought last year.
-
Sun Pharma Expects Ranbaxy Costs to Hit FY16 Revenue
Sun Pharmaceutical Industries Ltd, India's largest drug maker, said on Monday that its revenue in fiscal year 2016 would be flat at best as it struggles to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.
-
Sun Pharma Misses Profit Estimates in Q4 on Ranbaxy Costs
Sun Pharmaceutical Industries Ltd, India's largest drug maker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd.
-
Complaint Against Sun Pharma for Anti-Trust Violations in US
Drug major Sun Pharmaceutical Industries on Friday said it is reviewing a complaint filed against it and its subsidiaries by Meijer Inc alleging anti-trust and other violations in connection with Ranbaxy securing market exclusivity for certain products.
